Mirum Pharmaceuticals (NASDAQ:MIRM) Raised to “Moderate Buy” at Royal Bank Of Canada

Mirum Pharmaceuticals (NASDAQ:MIRM) was upgraded by analysts at Royal Bank Of Canada to a “moderate buy” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other brokerages have also recently commented on MIRM. Evercore reissued an “outperform” rating and issued a $101.00 price objective on shares of Mirum Pharmaceuticals in a research note on Tuesday, January 20th. Leerink Partners set a $100.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, December 10th. HC Wainwright raised their target price on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a report on Monday, January 26th. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. Finally, Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.17.

Mirum Pharmaceuticals Stock Up 2.2%

Mirum Pharmaceuticals stock opened at $105.10 on Tuesday. Mirum Pharmaceuticals has a 12-month low of $36.88 and a 12-month high of $107.41. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $5.40 billion, a PE ratio of -122.21 and a beta of 0.49. The firm’s fifty day moving average is $88.64 and its 200 day moving average is $77.02.

Insiders Place Their Bets

In other news, SVP Jolanda Howe sold 968 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total transaction of $99,994.40. Following the completion of the transaction, the senior vice president directly owned 4,503 shares in the company, valued at $465,159.90. The trade was a 17.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Eric Bjerkholt sold 1,053 shares of the business’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $96.19, for a total value of $101,288.07. Following the transaction, the chief financial officer owned 43,741 shares of the company’s stock, valued at approximately $4,207,446.79. The trade was a 2.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 45,136 shares of company stock worth $4,352,029. Company insiders own 14.36% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several hedge funds have recently bought and sold shares of MIRM. Cullen Frost Bankers Inc. purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at $30,000. MCF Advisors LLC grew its stake in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth about $32,000. CIBC Private Wealth Group LLC bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at about $32,000. Finally, Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at about $33,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.